Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 199

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 199
---
 itself. Remit of the Board of Directors The Board of Directors establishes the orientation of the Company’s activities and ensures that they are implemented, paying due consideration to social and environmental issues. Subject to those powers expressly attributed to Shareholders’ General Meetings and within the limits set by the corporate purpose, the Board addresses any issue of relevance to the proper conduct of the Company’s affairs and, through its deliberations, settles matters concerning the Company. French law, Articles of Association and Board Charter The rules and operating procedures of our Board of Directors are defined by French law, by our Articles of Association, and by our Board Charter (English language versions of which are reproduced in full as Exhibit 1.1 and Exhibit 1.2 to this annual report). Our Board Charter describes the rights and obligations of Board members; the composition, role and operating procedures of the Board of Directors and Board Committees; and the roles and powers of the Chairman and the Chief Executive Officer. It is prepared in accordance with the French Commercial Code and our Articles of Association. Composition of the Board of Directors As of December 31, 2024, the Sanofi Board of Directors had 17 members, including 12 independent directors and two directors representing employees; 47 % of our Board members were women (excluding directors representing employees, in accordance with Order no. 2024-934 of October 15, 2024 transposing into French law Directive (EU) 2022/2381 of the European Parliament and of the Council of November 23, 2022 on improving the gender balance among directors of listed companies and related measures); and 41% were non-French nationals (including directors representing employees). On January 1, 2025, Jean-Paul Kress joined the Sanofi Board of Directors, following the Board's decision to co-opt him as an independent director, replacing Gilles Schnepp, who resigned from office, effective December 31, 2024. In accordance with French law, Mr. Kress’s appointment must be ratified by the shareholders at the Annual General Meeting of April 30, 2025, in which case Mr. Kress will serve for the remainder of Gilles Schnepp’s term of office, i.e. until the close of the Annual General Meeting held in 2026 to approve the financial statements for the accounts for the year ended December 31, 2025. Following this co-option, the proportion of women and of non-French nationals (including directors representing employees) remains unchanged. The